1. Sarvet AL, Wall MM, Keyes KM, et al. Recent rapid decrease in adolescents’ perception that marijuana is harmful, but no concurrent increase in use. Drug Alcohol Depend . 2018;186:68-74.
2. Compton WM, Han B, Jones CM, Blanco C, Hughes A. Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. Lancet Psychiatry . 2016;3:954-964.
3. Lapham GT, Lee AK, Caldeiro RM, et al. Frequency of cannabis use among primary care patients in Washington state. J Am Board Fam Med . 2017;30:795‐805.
4. Chandra S, Radwan MM, Majumdar CG, et al. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci . 2019;269:5-15.
5. Sevigny EL, Pacula RL, Heaton P. The effects of medical marijuana laws on potency. Int J Drug Policy . 2014;25:308-319.
6. Monte AA, Shelton SK, Mills E, et al. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med . 2019;170:531-537.
7. Scott JC, Slomiak ST, Jones JD, et al. Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry . 2018;75:585-595.
8. Gruber SA, Sagar KA, Dahlgren MK, et al. Age of onset of marijuana use and executive function. Psychol Addict Behav . 2012;26:496-506.
9. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A . 2012;109:E2657-E2664.
10. Mammen G, Rueda S, Roerecke M, et al. Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. J Clin Psychiatry . 2018;79:17r11839.
11. Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry . 2016;79:549-556.
12. Singh A, Saluja S, Kumar A, et al. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther . 2018;7:45-59.
13. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med . 2014;370:2219-2227.
14. Bari M, Battista N, Pirazzi V, et al. The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci (Landmark Ed) . 2011;16:498-516.
15. Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res . 2012;71:215-219.
16. Saurel-Cubizolles M-J, Prunet C, Blondel B. Cannabis use during pregnancy in France in 2010. BJOG . 2014;121:971-977.
17. Prunet C, Delnord M, Saurel-Cubizolles M-J, et al. Risk factors of preterm birth in France in 2010 and changes since 1995: results from the French national perinatal surveys. J Gynecol Obstet Hum Reprod . 2017;46:19-28.
18. Kondrad EC, Reed AJ, Simpson MJ, et al. Lack of communication about medical marijuana use between doctors and their patients. J Am Board Fam Med . 2018;31:805-808.
19. Casajuana C, López-Pelayo H, Balcells MM, et al. Definitions of risky and problematic cannabis use: a systematic review. Subst Use Misuse . 2016;51:1760-1770.
20. Norberg MM, Gates P, Dillon P, et al. Screening and managing cannabis use: comparing GP’s and nurses’ knowledge, beliefs, and behavior. Subst Abuse Treat Prev Policy . 2012;7:31.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington DC: APA Publishing; 2013:509-516.
22. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry . 2015;72:1235-1242.
23. Smith PC, Schmidt SM, Allensworth-Davies D, et al. A single-question screening test for drug use in primary care. Arch Intern Med . 2010;170:1155-1160.
24. Fischer B, Jones W, Shuper P, et al. 12-month follow-up of an exploratory ‘brief intervention’ for high-frequency cannabis users among Canadian university students. Subst Abuse Treat Prev Policy . 2012;7:15.
25. Turner SD, Spithoff S, Kahan M. Approach to cannabis use disorder in primary care: focus on youth and other high-risk users. Can Fam Physician . 2014;60:801-808.
26. Smart R, Caulkins JP, Kilmer B, et al. Variation in cannabis potency & prices in a newly-legal market: evidence from 30 million cannabis sales in Washington State. Addiction . 2017;112:2167-2177.
27. Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling accuracy of cannabidiol extracts sold online. JAMA . 2017;318:1708-1709.
28. Richards JR, Bing ML, Moulin AK, et al. Cannabis use and acute coronary syndrome. Clin Toxicol (Phila) . 2019;57:831-841.
29. Subramaniam VN, Menezes AR, DeSchutter A, et al. The cardiovascular effects of marijuana: are the potential adverse effects worth the high? Mo Med . 2019;116:146-153.
30. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol . 2002;42:58S-63S.
31. Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med . 2007;167:221-228.
32. Bramness JG, von Soest T. A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults. BMC Pulm Med . 2019;19:52.
33. Moore BA, Augustson EM, Moser RP, et al. Respiratory effects of marijuana and tobacco use in a U.S. sample. J Gen Intern Med . 2005;20:33-37.
34. Tashkin DP. Does marijuana pose risks for chronic airflow obstruction? Ann Am Thorac Soc . 2015;12:235-236.
35. McGuire PK, Jones P, Harvey I, et al. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res . 1995;15:277-281.
36. Hall W, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry . 2008;7:68-71.
37. Gerlach J, Koret B, Gereš N, et al. Clinical challenges in patients with first episode psychosis and cannabis use: mini-review and a case study. Psychiatr Danub . 2019;31(suppl 2):162-170.
38. Patel R, Wilson R, Jackson R, et al. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open . 2016;6:e009888.
39. Day NL, Richardson GA, Goldschmidt L, et al. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol . 1994;16:169-175.
40. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol . 2000;22:325-336.
41. Corsi DJ, Walsh L, Weiss D, et al. Association between self-reported prenatal cannabis use and maternal, perinatal, and neonatal outcomes. JAMA . 2019;322:145-152.
42. Baker T, Datta P, Rewers-Felkins K, et al. Transfer of inhaled cannabis into human breast milk. Obstet Gynecol . 2018;131:783-788.
43. Thompson K, Leadbeater B, Ames M, et al. Associations between marijuana use trajectories and educational and occupational success in young adulthood. Prev Sci . 2019;20:257-269.
44. Yuan M, Kanellopoulos T, Kotbi N. Cannabis use and psychiatric illness in the context of medical marijuana legalization: a clinical perspective. Gen Hosp Psychiatry . 2019;61:82-83.
45. Ronen A, Gershon P, Drobiner H, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev . 2008;40:926-934.
46. Robbe H. Marijuana’s impairing effects on driving are moderate when taken alone but severe when combined with alcohol. Hum Psychopharmacol Clin Exp . 1998;13(suppl 2):S70-S78.
47. Lenné MG, Dietze PM, Triggs TJ, et al. The effects of cannabis and alcohol on simulated arterial driving: influences of driving experience and task demand. Accid Anal Prev . 2010;42:859-866.
48. Anderson BM, Rizzo M, Block RI, et al. Sex differences in the effects of marijuana on simulated driving performance. J Psychoactive Drugs . 2010;42:19-30.
49. Laumon B, Gadegbeku B, Martin J-L, Biecheler M-B. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ . 2005;331:1371.
50. Asbridge M, Poulin C, Donato A. Motor vehicle collision risk and driving under the influence of cannabis: evidence from adolescents in Atlantic Canada. Accid Anal Prev . 2005;37:1025-1034.
51. Mann RE, Adlaf E, Zhao J, et al. Cannabis use and self-reported collisions in a representative sample of adult drivers. J Safety Res . 2007;38:669-674.
52. Taylor J, Wiens T, Peterson J, et al. Characteristics of e-cigarette, or vaping, products used by patients with associated lung injury and products seized by law enforcement—Minnesota, 2018 and 2019. MMWR Morb Mortal Wkly Rep . 2019;68:1096-1100.
53. Hancock-Allen JB, Barker L, VanDyke M, et al. Notes from the field: death following ingestion of an edible marijuana product—Colorado, March 2014. MMWR Morb Mortal Wkly Rep . 2015;64:771-772.
54. Murray RM, Quigley H, Quattrone D, et al. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry . 2016;15:195-204.
55. Di Forti MD, Sallis H, Allegri F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull . 2014;40:1509-1517.
56. Miller WR. Motivational interviewing: research, practice, and puzzles. Addict Behav . 1996;21:835-842.
57. Gates PJ, Sabioni P, Copeland J, et al. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev . 2016;(5):CD005336.
58. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry . 2015;76:1174-1180.
59. Cougle JR, Bonn-Miller MO, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav . 2011;25:554-558.
60. Johnson MJ, Pierce JD, Mavandadi S, et al. Mental health symptom severity in cannabis using and non-using veterans with probable PTSD. J Affect Disord . 2016;190:439-442.
61. Wilkinson ST, Radhakrishnan R, D’Souza DC. A systematic review of the evidence for medical marijuana in psychiatric indications. J Clin Psychiatry . 2016;77:1050-1064.
62. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry . 2019;6:995-1010.
63. Bonnet U, Preuss U. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil . 2017;8:9-37.
64. Vandrey R, Smith MT, McCann UD, et al. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend . 2011;117:38-44.
65. Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology . 2012;37:1689-1698.
66. Weinstein A, Miller H, Tal E, et al. Treatment of cannabis withdrawal syndrome using cognitive-behavioral therapy and relapse prevention for cannabis dependence. J Groups Addict Recover . 2010;5:240-263.
